transitioning from tirzepatide to retatrutide RETATRUTIDE: A Medication for Diabetes and Weight Loss What is the recommended protocol

Notably, in a recent chemical screen in the ferroptosis-sensitive HT-1080 N fibrosarcoma cells, seven out of eight PI3K/mTOR inhibitors suppressed the ferroptosis-inducing activity of erastin and sorafenib, but not the covalent GPX4 inhibitor, ML162 19

9 BombaM.GranzottoA.CastelliV.MassettiN.SilvestriE.CanzonieroL.et al (2018)

doi: 10.1016/j.pop.2020.08.004 [DOI] [PubMed] [Google Scholar] 10

When to contact your healthcare provider: Severe or persistent nausea and vomiting that prevents adequate oral intake Signs of dehydration (decreased urination, dizziness, dry mouth) Severe abdominal pain, especially if persistent or radiating to the back Symptoms of hypoglycemia if taking tirzepatide with insulin or sulfonylureas (shakiness, sweating, confusion, rapid heartbeat) Unusual injection site reactions (severe pain, swelling, redness) Intractable vomiting or inability to keep fluids down Any other concerning symptoms For future injections: Review proper injection technique with your healthcare provider or a diabetes educator before your next dose